Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. By reducing the amount of exposure to sunlight (or tanning lights) that are required to achieve a desired level of tanning, zeaxanthin can reduce the risks of skin cancer, premature aging or wrinkling, and similar skin problems. Since zeaxanthin also has retina-protecting properties and reduces the risk of a disease called macular degeneration, oral ingestion of these dosages of a zeaxanthin to enhance a tanned appearance and/or to protect against sun damage is believed to pose no health risks, and can offer several benefits due to the anti-oxidant and other activities of zeaxanthin.
1. A method of inhibiting adverse effects of ultraviolet radiation on human skin, comprising the step of ingesting a formulation containing at least about 20 milligrams of zeaxanthin per day over a span of at least about 5 days prior to sustained exposure to ultraviolet radiation, to cause a measurable decrease of skin susceptibility to damage by ultraviolet radiation, the zeaxanthin being the predominant carotenoid in the formulation and being predominantly present in the form of the R—R stereoisomer.
2. The method of claim 1 , wherein the decrease of skin susceptibility to damage by ultraviolet radiation is measured by demonstrating an increase in a person's ability to withstand a fixed dosage of ultraviolet radiation without suffering erythema.
3. The method of claim 1 , wherein the formulation is in the form of one of the group consisting of a capsule, tablet, and a liquid.
4. The method of claim 1 wherein the decrease of skin susceptibility to damage by ultraviolet radiation is measured by a visual examination which confirms a noticeable darkening of skin tint following commencement of zeaxanthin ingestion.
5. The method of claim 1 , wherein the formulation containing zeaxanthin is formulated in an oily carrier substance.
6. The method of claim 1 , wherein at least one second active agent is also ingested in a dosage which is believed to induce darker skin tint in at least some people.
7. The method of claim 6 , wherein the second agent is selected from the group consisting of melanocyte-stimulating hormone, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine.
8. The method of claim 1 wherein the ingestion of zeaxanthin is also accompanied by a step which comprises exposing at least one area of skin to ultraviolet radiation at a level which induces melanin production within the exposed area of skin, thereby creating a combination of elevated zeaxanthin concentration and elevated melanin combination in one or more epidermal layers in the exposed area of skin.
9. The method of claim 1 , wherein the formulation of zeaxanthin contains in a range from about 30 milligrams to about 100 milligrams per day of zeaxanthin.